Mylan (MYL) volatility flat into announces FDA approval of ANDAs for Glatiramer Acetate Injection
Tweet
Share
E-mail
Get Alerts MYL Hot Sheet
Join SI Premium – FREE
Mylan (NASDAQ: MYL) October weekly call option implied volatility is at 30, October is at 28, November is at 34; compared to its 52-week range of 23 to 51 into announcing the FDA approval of ANDAs for Glatiramer Acetate Injection.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX Shares Indicated To Open At $155
- In memo, Meta says it plans to crack down on employee token use as AI costs soar - The Information
- SpaceX (SPCX) reaches new intraday/all-time highs
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
